Last but not least, as both obesity and NAFLD may lead to the development of HCC, and in the absence of any approved medication specifically for NAFLD, it should be evaluated whether targeting obesity may prevent NAFLD-associated HCC, by affecting adiponectin and/or TNF-α production. This evidence concerns the gene ADIPOQ and obesity due to melanocortin 4 receptor deficiency.